CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Cheryl Blanchard

Executive Chair, Anika Therapeutics, Inc.

Search every verified Cheryl Blanchard interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Cheryl Blanchard, president and CEO of Anika Therapeutics, has discussed the company's strategic transformation from a biomaterials firm into a global joint preservation business. In podcast appearances, she described how the 2020 acquisitions of Arthrosurface and Parcus Medical shortened Anika's innovation cycles and expanded its addressable market from approximately $1 billion to $8 billion. Blanchard attributed the company's focus on ambulatory surgery centers (ASCs) and early intervention orthopedics to a pre-COVID strategy, noting that patient demand for timely procedures grew during the pandemic as people rejected the notion that orthopedic surgeries were elective. Blanchard also emphasized the importance of cultural integration in mergers and acquisitions, stating that the success of such deals depends on retaining talent and aligning teams around a shared vision. She highlighted the need for all stakeholders in the healthcare ecosystem—including surgeons, facilities, insurers, and patients—to find financial value, quoting her CFO's phrase "no margin, no mission." She described Anika's history, including its founding in 1992 and its hyaluronic acid-based products such as Orthovisc and Monovisc, which she said hold the number one market share for osteoarthritis pain management.

Recent appearances

  • Trends and Innovations in Orthopaedics: A CEO’s Perspective With Guest Cheryl Blanchard, PhD

    November 05, 2024 · 📺 The American Orthopaedic Association

    Trends and Innovations in Orthopaedics: A CEO’s Perspective  Hosts Charles A. Goldfarb, MD, FAOA and Alexander Aleem, MD sit down with Cheryl Blanchard, BS, MS, PhD, president and CEO of Anika Therapeutics, to discuss how the company is driving technological innovations to benefit patients, orthopaedic surgeons, payors, and health care organizations. Dr. Blanchard discusses how new orthopaedic trends impact the development process and shape product offerings. She describes how the 2020 acquisitions of Arthrosurface and Parcus Medical have dramatically shortened Anika’s innovation cycles to…

    Watch on YouTube ↗

  • How Anika Therapeutics is using M&A and R&D to evolve into a global joint preservation business

    August 05, 2024 · 📺 DeviceTalks

    In this episode, Cheryl R. Blanchard, Ph.D., CEO of Anika Therapeutics, explains how the company is morphing from a biomaterials into a joint preservation business. In an interview with Tom Salemi, editorial director of DeviceTalks, Blanchard points to collaboration she had with biomedical greats over her career, including a formative connection with Ray Elliott, the former CEO of Zimmer. Today, through sizable M&A and internal development, Anika is building a portfolio of ortho biomaterials and new joints that gives is more shots on net. Blanchard explains how Anika’s opportunity has grown it…

    Watch on YouTube ↗

  • From Labs to Board Rooms: A CEO’s Unique Journey to Better Patients' Lives

    October 20, 2021 · 📺 Axtria Inc

    In this episode, Cheryl Blanchard, President and Chief Executive Officer of Anika Therapeutics, joins us to discuss her unique journey to bettering patients’ lives. First, Cheryl talks about how Anika Therapeutics has transformed over the past few years, and how technology has played a massive role in Anika’s transformation as a business. Every company has its own value system and culture; Cheryl explains how she merged different cultures into one coherent team. Tune in as we chat about the importance of everyone’s role in a company in the context of creating future therapies. IN THI…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →